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DOI 10.1016/j.ccr.2010.11.001SUMMARYAntibodies that block vascular endothelial growth factor (VEGF) have become an integral part of antiangio-
genic tumor therapy, and antibodies targeting other VEGFs and receptors (VEGFRs) are in clinical trials.
Typically receptor-blocking antibodies are targeted to the VEGFR ligand-binding site. Here we describe
a monoclonal antibody that inhibits VEGFR-3 homodimer and VEGFR-3/VEGFR-2 heterodimer formation,
signal transduction, as well as ligand-induced migration and sprouting of microvascular endothelial cells.
Importantly, we show that combined use of antibodies blocking ligand binding and receptor dimerization
improves VEGFR inhibition and results in stronger inhibition of endothelial sprouting and vascular network
formation in vivo. These results suggest that receptor dimerization inhibitors could be used to enhance anti-
angiogenic activity of antibodies blocking ligand binding in tumor therapy.INTRODUCTION (VEGFR) tyrosine kinases in endothelial cells (Tammela et al.Angiogenesis is the growth of new blood vessels from preexist-
ing vasculature. The importance of angiogenesis for the growth
of tumors was realized decades ago (Folkman, 1971), and the
first antiangiogenic agents have recently been approved for clin-
ical use (Jain et al., 2006). Although these treatments have been
highly successful in the treatment of many types of solid tumors,
most patients are either refractory or eventually acquire resis-
tance to antiangiogenic therapy (Jain et al., 2009; Crawford
and Ferrara, 2009). Therefore novel antiangiogenic therapeutics
are needed to complement existing therapies.
Vascular endothelial growth factors (VEGFs) stimulate angio-
genesis and lymphangiogenesis by activating VEGF receptorSignificance
Antiangiogenic therapeutics are nowwidely used in the treatme
not all patients respond, whereas others become refractory to t
improved antiangiogenic therapeutics. Here we report a mo
VEGFR-3 homodimers and VEGFR-3/VEGFR-2 heterodimers, w
Our data suggest that employing a combination of ligand bindin
ing of VEGFR activation for enhanced inhibition of tumor angio
630 Cancer Cell 18, 630–640, December 14, 2010 ª2010 Elsevier Inc,
2005). VEGFR-3 (also known as Flt4) belongs to this family
that, in addition, comprises VEGFR-1/Flt-1 and VEGFR-2/KDR/
Flk-1 (Alitalo et al., 2005; Shibuya and Claesson-Welsh, 2006).
Mice deficient in the Vegfr3 gene die in utero due to abnormal
development of the blood vasculature resulting in cardiovascular
failure (Dumont et al., 1998). On the other hand, loss of the
VEGFR-3 ligand Vegfc results in embryonic lethality due to lack
of lymphatic vessel formation (Ka¨rkka¨inen et al., 2004).
The Vegfr3 gene is expressed in the entire vasculature of the
developing embryo, but expression becomes restricted to the
lymphatic system and a few specialized fenestrated blood vessel
endothelia in adults (Partanen et al., 2000; Kaipainen et al., 1995).
However, expression of VEGFR-3 is again induced in thent of solidmalignancies, but according to clinical experience
herapy. Thus there is high demand for a second generation of
noclonal antibody that acts by inhibiting the formation of
hich arewell-established targets for antiangiogenic therapy.
g and dimerization inhibitors provides more effective block-
genesis and lymphangiogenesis in vivo.
.
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A More Effective VEGFR Blocking Mechanismangiogenic blood vascular endothelium in tumors (Valtola et al.,
1999; Partanen et al., 2000; Tammela et al., 2008). Several
studies have shown that interference with VEGFR-3 function
inhibits tumor lymphangiogenesis and metastasis in mice (He
et al., 2002; Alitalo et al., 2005). Specific targeting of VEGFR-3
can be achieved by small molecular weight tyrosine kinase inhib-
itors (Heckman et al., 2008), by trapping the VEGFR-3 ligands
VEGF-C and VEGF-D with soluble extracellular domain of
VEGFR-3 (Burton et al., 2008; Jeon et al., 2008; Ma¨kinen et al.,
2001) or by VEGFR-3 blocking monoclonal antibodies (Persaud
et al., 2004). Recent evidence has also suggested that blocking
VEGFR-3 can improve the inhibition of tumor growth obtained
with other antiangiogenic therapies (Tammela et al., 2008).
Current VEGFR-2 and VEGFR-3 blocking antibodies are
directed against the ligand binding domains of these receptors
(Hicklin et al., 2001; Witte et al., 1998; Pytowski et al., 2005;
Persaud et al., 2004). Thus far other types of function-blocking
antibodies against the VEGFR tyrosine kinases have not been
described. Analogies to alternative modes of receptor tyrosine
kinase inhibition can be derived from published work on the
epidermal growth factor receptor (EGFR) family. For example,
trastuzumab, a potent anti-ErbB2 antibody, inhibits the activa-
tion of this ligand-less receptor via mechanisms apparently
involving antibody-dependent cellular cytotoxicity or inhibition
of the proteolytic shedding of ErbB2 (Valabrega et al., 2007;
Hynes and Lane, 2005).
Here we report on antibodies directed against the VEGFR-3
extracellular domain that inhibit receptor dimerization, and
show that their combination with antibodies blocking ligand
binding results in more effective inhibition of VEGFR-3 activation
and vascular network formation in vitro and in vivo.
RESULTS
Characterization of the 2E11 Anti-VEGFR-3 Antibody
Monoclonal antibodies against the extracellular domain of
VEGFR-3 were tested for blocking of VEGFR-3 activation and
survival/proliferation of BaF3 cells expressing a VEGFR-3/eryth-
ropoietin (Epo) receptor chimera. In the absence of IL-3 these
cells survive only in the presence of a VEGFR-3 ligand in the
culture medium (Ma¨kinen et al., 2001). Figure 1A shows
a comparison of four antibodies in this assay. As can be seen
from the figure, the addition of increasing amounts of the 2E11
antibody, but not of 9D9 or AFL4 antibodies to the medium con-
taining 25 ng/ml human recombinant VEGF-C inhibited the
survival of the cells. The previously publishedmonoclonal human
anti-human VEGFR-3 antibody 3C5 (Persaud et al., 2004) and
the previously published VEGFR-3-Ig soluble receptor (Ma¨kinen
et al., 2001) were used as positive controls for VEGFR-3 inhibi-
tion. The inhibition of VEGFR-3 activation by the 2E11 and 3C5
antibodies was confirmed by using VEGF-C induced VEGFR-3
phosphorylation in endothelial cells (Figure 1B).
A common mechanism for antibody inhibition of receptor
activation is to block ligand binding to the receptor. It has been
shown that the 3C5 antibody strongly inhibits the binding of
VEGF-C to VEGFR-3 and the VEGF-C-induced mitogenic
response in cells that expresses a chimeric human VEGFR-3-
FMS receptor (Persaudet al., 2004). However, unlike the3C5anti-
body, the 2E11 antibody did not block the binding of VEGFR-3Canextracellular domain to immobilized VEGF-C (Figures 1C and
1D). These data indicated that although 2E11 and3C5both inhibit
VEGFR-3 activation, their inhibition mechanisms are different.
The binding epitopes of AFL4 and 9D9 were mapped to linear
peptide sequences in VEGFR-3 immunoglobulin homology
domain 5 (D5) and D6, respectively (see Figures S1A and S1B
available online). In contrast, the 2E11 binding site could not
be mapped to a linear epitope, nor was the epitope in the ligand
binding region (D1–D3), as this antibody recognized VEGFR-3
where this region had been deleted (Figure S1C). Furthermore,
2E11 bound to nonreduced but not to reduced VEGFR-3
polypeptides in western blotting analysis (Figure S2B), suggest-
ing that the epitope is conformational and sensitive to denatur-
ation of VEGFR-3. Figure S1D shows the Kd values for 2E11,
9D9, and AFL4 obtained from surface plasmon resonance
analysis using monomeric VEGFR-3D1-7. Because the 2E11
antibody bound better to the nonreduced receptor, we searched
for the binding epitope in D5 that undergoes proteolytic cleavage
after receptor biosynthesis, rendering the remaining fragments
bound by a disulfide bridge (Pajusola et al., 1994).
A Polypeptide Loop Extending from the VEGFR-3 D5
Is Critical for 2E11 Antibody Binding and Receptor
Activation
Figure S2A shows the sequence comparison of D5 in human and
mouse VEGFR-3 and VEGFR-2. The proteolytic cleavage site in
VEGFR-3 (Lee et al., 1996) is marked with a red arrowhead and
the cysteine residues are marked red. Figures S2C and S2D
showacomputermodel of aVEGFR-3D5-relatedstructurebased
on the immunoglobulin-homologydomainofmyelin basicprotein-
C (KelleyandSternberg, 2009; Idowuet al., 2003). InVEGFR-3D5,
the extended loop (underlined in Figure S2A; containing the
SLRRRQQQ sequence) would contain the cleavage site between
R472 and S473 (red arrowhead in Figures S2A and S2C). In Fig-
ure S2D the surface of the immunoglobulin homology domain is
colored red for negative charge and blue for positive charge.
Although no actual data is available for a possible D5-D5 interac-
tion, this model suggested a possible scenario where the posi-
tively charged residues of the elongated loop ‘‘arm’’ could contact
the negatively charged surface of the ‘‘armpit,’’ thus contributing
to dimer stabilization and activation of the receptor.
Figure 2A schematically outlines themutagenesis strategy used
to interrogate the importanceofD5and itselongated,cleaved loop
structure for 2E11 antibody binding and receptor function. The
disulfidebonds in the figure are hypothetical andbasedondeduc-
tions fromtheD5model. TheeffectofD5cysteine toserine residue
replacements on VEGFR-3 expression, cleavage and autophos-
phorylation in transfected 293T cells in the absence and presence
ofVEGF-Careshown inFigure2B (left panel). The transfectedcells
were analyzed by VEGFR-3 immunoprecipitation and western
blotting using anti-phosphotyrosine (pY) or VEGFR-3 antibodies.
As can be seen from the results, the C445S and C534Smutations
and their combination prevented receptor autophosphorylation
and processing. The C466S mutation decreased VEGFR-3
expression levels while retaining at least some phosphorylation,
and blocked cleavage of the receptor, whereas C486S allowed
both processing and ligand-induced phosphorylation.
A similar analysis was carried out with a chimeric VEGFR-3
receptor where the loop region was substituted with thecer Cell 18, 630–640, December 14, 2010 ª2010 Elsevier Inc. 631
Figure 1. Characterization of the VEGFR-3 Blocking Antibodies
(A) VEGFR-3/BaF3 cell survival assay in the presence of the indicated anti-VEGFR-3 antibodies and 25 ng/ml of full-length (FL) or proteolytically processed,
mature (DNDC) VEGF-C (Joukov et al., 1997), as indicated. The IC50 values for VEGF-CFL are 3C5, 0.2 nM; 2E11, 0.66 nM; VEGFR-3-Ig, 0.79 nM; and for
DNDC VEGF-C: 3C5, 1.6 nM; 2E11, 2.2 nM. Error bars represent ± SEM.
(B) Antibody inhibition of VEGFR-3 phosphorylation in HDME cells stimulated with VEGF-C in the presence or absence of the indicated antibodies. Lysates were
precipitated with polyclonal VEGFR-3 antibodies and blotted with pTyr (pY) or VEGFR-3 antibodies, as shown.
(C) Antibody-mediated inhibition of ligand binding to VEGFR-3. Wells were precoated with VEGF-C. Recombinant extracellular domain of VEGFR-3 with or
without the indicated antibodies was applied, and the bound proteins were analyzed in western blotting with anti-VEGFR-3 antibodies.
(D) Wells were precoated as above. Recombinant VEGFR-3-AP was preincubated with different concentrations of either 2E11 or 3C5 antibodies and applied for
binding. After washes, alkaline phosphatase activity was measured at OD405. See also Figure S1.
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A More Effective VEGFR Blocking Mechanismcorresponding amino acid sequence of VEGFR-2, or where the
loop was deleted. As shown in Figure 2C, the loop swap (LS)
from VEGFR-2 to VEGFR-3 leads to slightly decreased
VEGFR-3 phosphorylation and loss of both the chimeric
VEGFR-3 cleavage and VEGF-C-inducible activation. In
contrast, loop deletion (LD) leads to significant decrease of
receptor phosphorylation even in the presence of VEGF-C.
These results suggested that D5 plays a crucial role in VEGFR-
3 activation.
As point mutations and deletions in the D5 loop area of
VEGFR-3 had a significant effect on VEGFR-3 activation, the
2E11 antibodies were tested for binding to the different
VEGFR-3 constructs in transient transfection experiments. As
shown in Figure 2D and Figure S2E, the 2E11 antibodies do
not recognize VEGFR-3 LD, but recognize VEGFR-3 LS, and
they also failed to detect VEGFR-2 expressed in 293T cells
(data not shown). When the other VEGFR-3 mutants were
expressed in 293T cells and precipitated with 2E11 or 9D9 fol-
lowed by western blotting with 9D9 antibodies, 2E11 failed to632 Cancer Cell 18, 630–640, December 14, 2010 ª2010 Elsevier Incprecipitate those mutants that had lost VEGF-C inducible activa-
tion (Figure 2E). These data indicate that the 2E11 epitope is at
least partially located in D5 and sensitive to conformational
changes in the loop region. Furthermore, the 2E11 antibodies
recognize an epitope that correlates with the ability of the
receptor to be activated. Although the mutagenesis data
strongly suggested that the 2E11 epitope is located in VEGFR-
3 D5, it was not possible to map this epitope using linear
peptides. To further prove that 2E11 recognizes D5, this domain
was expressed in 293T cells. As shown in Figure 2F, the 2E11
(and AFL4) antibodies readily precipitated the D5 domain from
the conditioned medium, whereas the 9D9 antibodies did not,
because the 9D9 epitope maps to D6 (Figure S1A).
2E11 Antibodies Provide Synergistic Inhibition
of VEGFR-3 Activation in Combination with Antibodies
Blocking Ligand Binding
The above experiments showed that the 3C5 and 2E11 anti-
bodies bind to different regions of VEGFR-3 and inhibit receptor.
Figure 2. VEGFR-3 Domain 5 Contains Structures Important for Antibody Binding and Receptor Activity
(A) Schematic presentation of mutationsmade in VEGFR-3 domain 5 (D5). Four point mutations: C445S, C466S, C486S, C534S, one double mutation: DS (C445S
and C534S combined), loop deletion (LD), and loop swap (LS) were made.
(B and C) Effect of the different mutations on VEGFR-3 activation and proteolytic processing. VEGFR-3 wt and mutants expressed in 293T cells were stimulated
with VEGF-C. VEGFR-3 was then precipitated and analyzed by western blotting with anti-pY or anti-VEGFR-3 antibodies.
(D) Binding of 2E11 antibody to VEGFR-3 LD and LS mutants. 293T cells transfected with the indicated mutants were stained with the 2E11 antibodies and
analyzed by flow cytometry (red). Green: mock transfected cells.
(E) Transfected 293T cell lysates were precipitated with 2E11 or 9D9 antibodies and blotted with the 9D9 antibody.
(F) The 2E11 antibodies recognize VEGFR-3 D5. VEGFR-3 D5 was cloned into the pSectag vector and expressed in 293T cells. Conditioned medium was precip-
itated either with 9D9, AFL4 or 2E11 antibodies and western blotted with AFL4 antibodies (upper panel). The lower panel represents the same samples immuno-
blotted with the secondary anti-rat antibody only. Asterixes indicate the IgG light chain. WT = wild-type. See also Figure S2.
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A More Effective VEGFR Blocking Mechanismactivity by different mechanisms. This raised a question of
possible synergistic inhibition of VEGFR-3 activity by 2E11 and
3C5. As shown in Figure 3A, the 2E11 and 3C5 antibodies in
combination blocked VEGFR-3 induced BaF3 cell survival better
than either antibody alone when VEGF-C was used at 10 ng/ml.
At this concentration of VEGF-C the combination of the anti-
bodies provided an additive effect (Figure 3A). At 100 ng/ml of
VEGF-C, 3C5 provided very little inhibition, whereas 2E11
retained some activity (Figure 3B). Strikingly, at this ligand
concentration, the two antibodies together provided synergistic
inhibition of VEGFR-3 activation. Thus these data indicate that
the two antibodies with the different mechanisms of inhibition
provide higher efficacy when used in combination. These data
also suggest that at high doses of VEGF-C the 3C5 antibodies
cannot efficiently block VEGFR-3 activation because theyCancompete with ligand binding, whereas the 2E11 antibodies retain
activity because their mechanism is based on blocking receptor
dimerization. Consistent with this hypothesis, the 3C5 antibodies
were not able to inhibit activation of the mitogen-activated
protein kinase Erk1,2 at high concentrations of VEGF-C in the
BaF cells expressing the VEGFR-3/EpoR chimera, although
2E11 showed efficient inhibition at all tested VEGF-C concentra-
tions (Figures 3C and 3D). Furthermore, as shown in Figure 3E,
a similar difference between the 2E11 and 3C5 antibodies was
detected in human dermal microvascular endothelial (HDME)
cells when VEGFR-3 phosphorylation was analyzed after stimu-
lation with different VEGF-C concentrations. Interestingly, only
the 2E11 antibody was able to inhibit some of the Erk1,2 phos-
phorylation induced by 25 ng/ml of VEGF-C, whereas inhibition
was not observed when using the 3C5 antibodies (Figure 3F).cer Cell 18, 630–640, December 14, 2010 ª2010 Elsevier Inc. 633
Figure 3. Inhibition of VEGFR-3 Activation
by the Combination of 2E11 and 3C5 Anti-
bodies
(A and B) Results of the VEGFR-3/BaF3 cell
survival assay done using the indicated anti-
VEGFR-3 antibody concentrations (mg/ml) in the
presence of 10 ng/ml (A) or 100 ng/ml (B) of proteo-
lytically processed, mature VEGF-C. Note that the
AFL4 antibody has no effect. The IC50 values for
10 ng/ml of DNDC VEGF-C are 2E11, 14.2 nM;
3C5, 2.64 nM; and 2E11 + 3C5, 1.38 nM. The
IC50 values for 100 ng/ml of DNDC VEGF-C are
2E11, 42.9 nM; 3C5, 204.6 nM; and 2E11 + 3C5,
11.2 nM.
(C) Antibody inhibition of Erk1,2 phosphorylation
in VEGFR-3/BaF3 cells stimulated with 25 ng/ml
of VEGF-C in the presence or absence of the indi-
cated antibodies at 2 mg/ml. Lysates were blotted
with pErk1,2 or tubulin antibodies, as shown.
(D) Antibody inhibition of Erk1,2 phosphorylation
in VEGFR-3/BaF3 cells stimulated with increasing
concentrations of VEGF-C in the presence or
absence of the indicated antibodies. Lysates
were blotted with pErk1,2 or tubulin antibodies,
as shown.
(E) Antibody inhibition of VEGFR-3 phosphoryla-
tion in HDME cells stimulated with increasing
concentrations of VEGF-C in the presence or
absence of the indicated antibodies. Lysates
were precipitated with polyclonal antibodies
against VEGFR-3 and blotted with pY or VEGFR-
3 antibodies.
(F) Antibody inhibition of Erk1,2 phosphorylation in
HDME cells stimulated with VEGF-C in the pres-
ence or absence of the indicated antibodies.
Lysates were blotted with pErk1,2 or Erk1,2 anti-
bodies.
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A More Effective VEGFR Blocking MechanismThe 2E11 Antibodies Inhibit VEGF-C Induced VEGFR-
2/VEGFR-3 Heterodimerization and VEGFR-2 Activation
Previous studies have shown that VEGF-C can induce the forma-
tion of VEGFR-2/VEGFR-3 heterodimers that show distinct
phosphorylation patterns in comparison with receptor homo-
dimers (Dixelius et al., 2003). We investigated the possibility
that 2E11, which inhibited VEGFR-3 activation by binding to
D5, could act in trans to inhibit also the formation of the
VEGFR-2/VEGFR-3 heterodimers. HDME cells expressing both
receptors were stimulated with VEGF-C in the presence of the
VEGFR-3 antibodies, VEGFR-3 was immunoprecipitated, and
the immune complexes were subjected to western blotting using
VEGFR-2 specific antibodies. As can be seen from the results634 Cancer Cell 18, 630–640, December 14, 2010 ª2010 Elsevier Inc.shown in Figure 4A, the two VEGFR-3
blocking antibodies (2E11 and 3C5) in-
hibited the formation of VEGFR-2/
VEGFR-3 heterodimers, whereas the
AFL4 antibodies did not significantly
decrease VEGFR-2 coprecipitation. Inter-
estingly, inhibition of heterodimer forma-
tion was associated with decreased
VEGFR-2 activation by VEGF-C, particu-
larly when the 2E11 antibodies were
used (Figure 4B), correlating with
decreased downstream signaling viaErk1,2 (Figure 3F). In contrast, VEGFR-2 homodimer signaling
was not affected by the 2E11 or 3C5 antibodies in transfected
porcine aortic endothelial (PAE) cells expressing only VEGFR-2
(Figure 4C). Furthermore, preincubation with the 2E11 or 3C5
antibodies did not affect VEGF-induced VEGFR-2, Erk1,2, or
Akt phosphorylation (Figure S3A; data not shown). Also, unlike
the VEGF-C, the blocking antibodies did not induce downregula-
tion of total VEGFR-2 or VEGFR-3 during a 60-min incubation
(Figure S3B). These results indicate that the 2E11 antibodies
inhibit signaling of both VEGFR-3 homodimers and VEGFR-3/
VEGFR-2 heterodimers.
Both of the 2E11 and 3C5 antibodies were able to inhibit all
VEGF-C induced Akt phosphorylation and a part of Erk1,2
Figure 4. Antibody Inhibition of VEGFR-3/
VEGFR-2 Heterodimerization, Signaling,
Endothelial Cell Migration, and Sprouting
(A) Inhibition of VEGFR-2/VEGFR-3 heterodimeri-
zation by VEGFR-3 blocking antibodies (2E11,
3C5) in HDME cells stimulated with 25 ng/ml of
VEGF-C. Lysates were precipitated with poly-
clonal VEGFR-3 antibodies and blotted with
VEGFR-2 or VEGFR-3 antibodies.
(B and C) Effects of the VEGFR-3 and VEGFR-2
(IMC1121B) blocking antibodies on (B) VEGFR-2
phosphorylation in HDME cells or (C) PAE-
VEGFR-2 cells stimulated with 25 ng/ml of
VEGF-C. Lysates were precipitated with poly-
clonal VEGFR-2 antibodies and blotted with pY
or VEGFR-2 antibodies.
(D) Effects of the VEGFR-3 and VEGFR-2 blocking
antibodies on VEGF-C-induced intracellular
signaling. HDME cells were preincubated with
the indicated antibodies for 15 min and then stim-
ulated with 25 ng/ml of VEGF-C for 20min. Subse-
quently, total lysates were analyzed for Erk1,2 and
Akt phosphorylation.
(E and F) Effect of the VEGFR-3 and VEGFR-2
blocking antibodies on (E) VEGF-C-induced
migration or (F) sprouting of HDME cells.
*p < 0.05 compared to hIgG. Error bars
represent ± SEM. See also Figure S3.
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A More Effective VEGFR Blocking Mechanismphosphorylation in HDME cells (Figure 4D). On the other hand,
IMC1121B antibodies that block VEGFR-2 had no effect on
VEGF-C induced Akt phosphorylation, whereas they partially in-
hibited Erk1,2 phosphorylation. However, combination of
IMC1121B with either 2E11 or 3C5 completely inhibited Erk1,2
activation. These results suggest that both VEGFR-2 and
VEGFR-3 contribute to Erk1,2 activation whereas Akt activation
is mostly induced by VEGFR-3.
The 2E11 Antibodies Inhibit VEGF-C Induced Migration
and Sprouting of Normal as Well as Transformed
Endothelial Cells
The effects of the VEGFR-3 blocking antibodies were next
analyzed in migration and sprouting assays using cultured
HDME cells (Figures 4E and 4F). The antibodies blocking
VEGFR-3 (2E11, 3C5) or VEGFR-2 (IMC1121B) all inhibited
HDME cell migration and sprouting from microbeads. As shown
by flow cytometric analysis in Figure S3C, the HDME cells used
consisted of almost equal proportions of blood vascular andCancer Cell 18, 630–640, Dlymphatic endothelial cells (BECs and
LECs, respectively). VEGFR-2 was ex-
pressed at similar levels in both BECs
and LECs (Figure S4A). Although the level
of VEGFR-3 was lower in BECs than in
LECs, it was strongly phosphorylated in
the BECs on VEGF-C stimulation (Fig-
ure S4B). As can be seen from Figures
5A and 5B, 2E11 inhibited the migration
of both LECs and BECs, whereas 3C5 in-
hibited only LECmigration. Similar results
were obtained in the LEC sprouting assay
(Figure 5C), whereas BECs did not sproutin this assay (data not shown). Importantly, the combination of
3C5 and 2E11 antibodies inhibited sprouting more effectively
than either antibody alone (Figure S4C).
As shown in Figure 5D, in LECs, both Erk1,2 and Akt phos-
phorylation were inhibited by blocking VEGFR-3 activation using
3C5 or 2E11 antibodies, whereas in BECs only the VEGFR-2
blocking antibodies (IMC1121B) inhibited Erk1,2 activation.
Furthermore, the very slight Akt activation seen in the VEGF-C
treated BECs was inhibited only by the IMC1121 antibodies.
Kaposi sarcoma herpesvirus (KSHV)-infected ECs represent
a biologically relevant model of KSHV-induced Kaposi sarcoma
(KS); these cells have been demonstrated to robustly express
VEGFR-3 (Carroll et al., 2004; Hong et al., 2004; Sivakumar
et al., 2008; Wang et al., 2004). Moreover, the KS tumors show
enhanced levels of VEGFR-3 and VEGF-C, which may play
a key role in KSHV biology as LECs are considered to be the
favored target of KSHV infection (Jussila et al., 1998; Skobe
et al., 1999; Wang et al., 2004). We therefore tested the effect
of the VEGFR-3 blocking antibodies on the capillary outgrowthecember 14, 2010 ª2010 Elsevier Inc. 635
Figure 5. Antibody Inhibition of Migration, Sprouting, and Intracellular Signaling of Blood Vascular as Well as Normal and Transformed
Lymphatic Endothelial Cells
Effect of VEGFR-3 and VEGFR-2 blocking antibodies on VEGF-C-induced migration of LECs (A) and BECs (B), LECs sprouting (C), and intracellular signaling (D).
Phase contrast images (E) and statistical analysis (F) of the sprouting of K-LEC spheroids in the presence or absence of VEGF-C and in the presence of IgG, 2E11,
3C5 (each at 10 mg/ml) or a mixture of 2E11 and 3C5 (5 + 5 mg/ml). Scale bar represents 100 mm. *p < 0.05, **p < 0.01, ***p < 0.001 compared to hIgG or as shown.
Error bars represent ± SEM. See also Figure S4.
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A More Effective VEGFR Blocking Mechanismof KSHV-infected LEC (K-LEC) spheroids grown in a crosslinked
3D fibrin matrix. Extensive sprouting in response to VEGF-C was
observed in the K-LEC spheroids (Figure 5E), whereas the
control LECs sprouted to a lesser extent (data not shown). In
the absence of VEGF-C, the sprouting was greatly reduced. To
assess the effect of the 2E11 and 3C5 antibodies on the sprout-
ing of K-LEC spheroids, the cultures were treated with 10 mg/ml636 Cancer Cell 18, 630–640, December 14, 2010 ª2010 Elsevier Incof 2E11 or 3C5 antibodies or with 5 mg/ml of both 2E11 and 3C5.
The IgG control did not influence the sprouting over the
untreated K-LEC spheroids in the presence of VEGF-C (data
not shown), whereas incubation with either 2E11 or 3C5 anti-
bodies reduced sprout outgrowth significantly. The combination
treatment with 2E11 and 3C5 antibodies led to a stronger inhibi-
tion of sprout outgrowth (Figures 5E and 5F)..
Figure 6. Effects of the 2E11 and 3C5 Anti-
bodies and Their Combination on the Inhibi-
tion of Vascular Network Formation In Vivo
(A and D) LECs (A) and BECs (D) transfected with
the fluorescent reporter mCherry (red) implanted
to the mouse ear in Matrigel; the mice were daily
administered the indicated blocking antibodies
by intraperitoneal injections. Arrowheads indicate
endothelial tubes. Note that the red signals in the
BEC sample treated with the antibody combina-
tion represent cells without tube formation. Scale
bar represents 100 mm.
(B, C, E, and F) Statistical analysis of the sizes of
EC clusters (B and E) and total EC area (C and F)
in the plugs in pixels/1000. *p < 0.05, ***p <
0.001. Error bars represent ± SEM.
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A More Effective VEGFR Blocking MechanismStrong Inhibition of Vascular Morphogenesis In Vivo
by the 2E11 and 3C5 Antibody Combination
To test if the antibodies blocking ligand binding and receptor
dimerization would be effective in vivo, we implanted human
BECs or LECs in VEGF-C containing Matrigel plugs into the
ears of immunodeficient NOD-SCID-gamma mice. We found
that the 2E11 and 3C5 antibodies suppressed LEC tube forma-
tion with similar efficiency (Figures 6A–6C). Importantly,
combining 2E11 to 3C5 provided a stronger inhibition of tube
formation than either blocking antibody alone at the same anti-
body dose (Figure 6B). Intriguingly, the combination of 2E11
and 3C5 also dramatically suppressed the survival of the trans-
planted LECs (Figures 6A and 6C and data not shown). The
2E11 and 3C5 combination also inhibited the ability of trans-
planted BECs to form vascular networks in vivo more efficiently
than either antibody alone (Figures 6D–6F). However, unlike for
the LECs, further suppression of BEC survival was not observed
when comparing the combination treatment to the single treat-
ments (Figure 6F). These results indicate that VEGF-C driven
tube formation and survival of LECs as well as the vascular
network formation of BECs are inhibited by the antibodies, and
most efficiently by the combination of the two antibodies.Cancer Cell 18, 630–640, DDISCUSSION
Here we describe an antibody that
inhibits humanVEGFR-3 via amechanism
that strikingly differs from other blocking
antibodies against VEGFRs. The 2E11
antibodies did not block VEGF-C binding
to VEGFR-3, yet they effectively inhibited
VEGFR-3 phosphorylation and mitogenic
signal transduction even at high concen-
trations of VEGF-C, when the 3C5 anti-
bodies that occupy the ligand binding
site in VEGFR-3 displayed only moderate
inhibition. Even more striking was the
synergy observed between inhibiting
VEGFR dimerization and the inhibition of
ligand binding.
Among the VEGFRs, only VEGFR-3
undergoes proteolytic processing, but
the biological role of the processing isnot known. Our previous studies have shown that processing
occurs only after the receptor is glycosylated and translocated
to the cell surface (Pajusola et al., 1994). In the present study,
mutagenesis of select cysteine resides in D5, where the process-
ing occurs, inhibited VEGFR-3 cleavage, but not phosphoryla-
tion of VEGFR-3 on VEGF-C stimulation. Our data also showed
that a receptor where the extended loop of VEGFR-3 D5,
including the cleavage site, is deleted or replaced by a corre-
sponding nonhomologous loop of VEGFR-2 D5, cannot be
cleaved, although this mutant also shows a small increase of
tyrosyl phosphorylation on ligand stimulation. Thus, proteolytic
cleavage of VEGFR-3 is not required for receptor activity, and
the extended loop of D5 where the cleavage occurs can be
exchanged with the corresponding, but nonhomologous loop
of VEGFR-2 without complete loss of ligand-stimulated activity.
It thus seems that the loop structure and its internal disulfide
bonds are important for maintaining a conformation in D5 that
supports receptor activity.
The VEGFRs transduce their signals according to the
consensus scheme for receptor tyrosine kinases: binding of
the ligand leads to receptor dimerization with close apposition
of the receptor intracellular domains and exposure of the kinaseecember 14, 2010 ª2010 Elsevier Inc. 637
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ates signal transduction cascades, which ultimately lead to
cellular responses such as proliferation, motility and survival.
Crystal structures of complexes of VEGF (Wiesmann et al.,
1997; Christinger et al., 1996) and PlGF (Christinger et al.,
2004) with domain 2 of VEGFR-1 (VEGFR-1D2) have been deter-
mined. Mutating the extracellular parts of VEGFR-1 and VEGFR-
2 revealed that both D2 and D3 are needed for high affinity VEGF
binding (Davis-Smyth et al., 1998; Fuh et al., 1998). Similarly, the
recently published analysis of the VEGF/VEGFR-2 complex by
electron microscopy suggested that VEGF binds to D2 and D3
(Ruch et al., 2007). Interestingly, two studies so far reported
that the VEGFR-2 dimers are further stabilized by receptor-
receptor contacts mediated by D4 and D7 (Yang et al., 2010;
Ruch et al., 2007). One could thus envision that antibodies
binding to the domains involved in dimeric receptor-receptor
contacts could interfere with the close apposition of the down-
stream tyrosine kinase domains, thus blocking receptor activity.
However, although no such antibodies have been previously
characterized for the VEGFR family, the present results show
one specific region of VEGFR-3 that allows the inhibition of its
homodimerization as well as heterodimerization with VEGFR-2.
It should be mentioned that the ErbB2 antibody trastuzumab,
one of the first monoclonal antibodies used in clinical practice,
acts through a mechanism not involving inhibition of ligand
binding because a soluble ligand for ErbB2 has not been found.
The exact mechanism of ErbB2 inhibition by trastuzumab is not
completely understood, but these antibodies have little effect on
ErbB2-ErbB3 heterodimerization (Agus et al., 2002). Rather they
are thought to act through antibody-dependent cellular cytotox-
icity or inhibition of ErbB2 shedding (Valabrega et al., 2007;
Hynes and Lane, 2005). Interestingly, another ErbB2 blocking
antibody, pertuzumab, acts through blocking heterodimerization
of ErbB2 with other members of the ErbB family by binding to
domain II and sterically masking a binding pocket necessary
for receptor-receptor interaction (Franklin et al., 2004). Thus in
addition to antibody-dependent cellular cytotoxicity, pertuzu-
mab binding directly inhibits ErbB2 heterodimerization, which
blocks the ErbB2 signaling cascade (Agus et al., 2002). This
difference between trastuzumab and pertuzumab explains why
pertuzumab is effective in carcinomas that express low levels
of ErbB2, whereas trastuzumab is not (Agus et al., 2002;
Mendoza et al., 2002).
Antibodies that block ligand binding to receptor need to
compete with the ligand for receptor binding, i.e., the outcome
of therapeutic targeting is dependent on the stoichiometry
between ligand and antibody. At high ligand concentrations
such antibodies are less effective than antibodies blocking
receptor dimerization, as seen in our analysis in the BaF3/
VEGFR-3 cultures. In the cultured microvascular endothelial
cells, only VEGFR-2/VEGFR-2 heterodimers, but not VEGFR-2
homodimers, were inhibited by the 2E11 antibodies. Importantly
however, our data indicated that a combination of antibodies
blocking ligand binding and receptor dimerization is more effec-
tive in inhibiting both blood vascular and lymphatic endothelial
cell sprouting, in particular sprout elongation, than either
antibody alone. This was also the case in the analysis of blood
and lymphatic endothelial vascular network formation in vivo in
matrigel plugs, where the antibody combination furthermore638 Cancer Cell 18, 630–640, December 14, 2010 ª2010 Elsevier Inccompromised the survival of lymphatic endothelial cells. Simi-
larly, stronger inhibition of sprouting was observed with LECs
transformed with the KSHV human tumor virus when the combi-
nation of antibodies was used. Depending on the assay, the
combination of blocking antibodies thus provided an additive
or a synergistic inhibition. It would be interesting to know if
such effects could be further improved by inclusion of the
recently published antibodies against neuropilin-2 that block
VEGF-C binding and LEC sprout elongation (Xu et al., 2010).
Encouraged by results on increased efficacy and accelerated
receptor downregulation by antibody combinations (Ben-Kasus
et al., 2009), three ongoing clinical trials are addressing if
a combination of trastuzumab and pertuzumab results in
a better therapeutic outcome than either of the two antibodies
alone (http://clinicaltrials.gov/ct2/results?term = trastuzumab+
pertuzumab). Although such studies have not yet been carried
out with VEGFR targeting antibodies, our data on vascular
network formation of BECs and LECs suggest that using
a combination of ligand binding and dimerization inhibitors
would provide more effective blocking of VEGFRs and enhanced
inhibition of tumor angiogenesis and lymphangiogenesis in vivo.
The combination could also form a potential treatment modality
for Kaposi sarcoma tumor cells that are known to expresses
VEGFR-3 (Jussila et al., 1998).
In conclusion, our results define a class of VEGFR blocking
antibodies, which provide interesting mechanistic insight into
receptor structure and activation. Importantly, the dimerization
inhibitor unveils a biologically meaningful rationale for suppress-
ing endothelial activation and angiogenesis in tumors. The use of
a combination of antibodies inhibiting ligand binding and
receptor dimerization should translate into improved antiangio-
genic and antilymphangiogenic therapies in the future.
EXPERIMENTAL PROCEDURES
Cell Culture
Human dermal microvascular endothelial cells (HDME cells), human lymphatic
endothelial cells (hLEC), and human blood vascular endothelial cells (hBEC)
were purchased from Promocell and cultured in endothelial cell medium MV
(Promocell) according to the supplier’s instructions. These cells were used
between passages 2–7. 293T cells (ATCC) were cultured in DMEM supple-
mented with 10% fetal calf serum (FCS). Porcine aortic endothelial cells
expressing VEGFR-2 were a kind gift from Dr. Lena Claesson-Welsh (Univer-
sity of Uppsala) (Waltenberger et al., 1994). The BaF3-VEGFR-3 cell line is
a genetically modified derivative of the murine pro-B cell line BaF3, which
stably expresses a chimeric receptor containing the extracellular domain of
human VEGFR-3 and the transmembrane and cytoplasmic domains of the
mouse erythropoietin receptor. These cells weremaintained in DMEMcontain-
ing 10% FCS. For maintenance, the cell cultures were supplemented with
2 ng/mL murine IL-3 (Calbiochem) and 250 mg/ml Zeocin (Invitrogen). In the
absence of IL-3, BaF3-VEGFR-3 cells grow only in presence of VEGF-C or
VEGF-D (Ma¨kinen et al., 2001).
Antibodies
The following primary antibodies were used in this study: mouse monoclonal
against human VEGFR-3, 2E11D11 (termed as 2E11 in the text), 9D9F9
(9D9, Available from Chemicon [Millipore, MAB3757] and ReliaTech [101-
M36]) (Jussila et al., 1998), rat monoclonal against mouse VEGFR-3: AFL4
(Kubo et al., 2000, available from eBioscience (14-5988)), IMC1121B
(ImClone), anti-phosphotyrosine (Millipore), anti-Podoplanin (Acris), anti-
Erk1/2, anti-phospho-Erk1/2, anti-Akt and anti-phospho-Akt (Cell Signaling).
The human antibody that blocks ligand binding to human VEGFR-3 (hF4-
3C5, termed 3C5 in the text) was generously provided by ImClone Systems.
Cancer Cell
A More Effective VEGFR Blocking Mechanism(Persaud et al., 2004). The polyclonal antibodies against VEGFR-3 were from
R&D Systems. Unless otherwise indicated, the blocking antibodies were
used at 2 mg/ml in the signal transduction experiments.
VEGF-C Binding Assay
A 96-well plate was precoated with 2 mg/ml VEGF-C and nonspecific binding
sites were blocked with 1% BSA. The extracellular domain of VEGFR-3 fused
to alkaline phosphatase (AP) (Pytowski et al., 2005) was preincubated with
different antibody concentrations for 20 min and then applied to the VEGF-C
precoated plates for 20 min. Subsequently, the plates were washed with
PBS and binding was detected by the addition of 50 ml alkaline phosphatase
substrate solution (Sigma). Alternatively, the extracellular domain of VEGFR-
3 (Jussila et al., 1998) was preincubated with the indicated antibodies and
applied to the VEGF-C coated plates for binding. After washing of the plates,
bound proteins were suspended in 100 ml 13 Laemmli buffer and analyzed by
immunoblotting with anti-VEGFR-3 antibodies.
Statistical Analysis
P values are determined by one-way ANOVA followed by Dunnett’s test using
SPSS 17.0 software. Statistical significance is indicated in the figures by *,
where p < 0.05; ** wherep < 0.01; and ***, where p < 0.001. The remaining
experimental procedures can be found in the Supplemental Experimental
Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and four figures and can be found with this article online at doi:10.1016/j.
ccr.2010.11.001.
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